Medications

Combined therapy makes headway for liver cancer

A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two ...

Oncology & Cancer

Combining CAR-T cells and inhibitor drugs for high-risk neuroblastoma

Chimeric antigen receptor (CAR)-T cell therapy is a potent emerging weapon against cancer, altering patients' T cells so they can better find and destroy tumor cells. But CAR-T cell therapy doesn't work well in every cancer—including ...

page 1 from 33